KRASG12C IN-17

KRASG12C IN-17 is an orally active covalent KRASG12C inhibitor, showing strong inhibitory activity in KRASG12C-mutant cancer cells (NCI-H23 IC50 = 0.7 nM; NCI-H358 IC50 = 0.5 nM) . KRASG12C IN-17 covalently and irreversibly binds to KRASG12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer[1].

Product Specifications

CAS Number

[2966924-23-0]

UNSPSC

12352005

Target

Ras

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Field of Research

Cancer

Smiles

N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C=C(F)C(C4=C5C(C#C)=CC=CC5=CC=C4)=C(F)C3=NC(OCC67CCCN6CCC7)=N2)C1

Molecular Formula

C37H33F3N6O2

Molecular Weight

650.69

References & Citations

[1]Gao K, et al. Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors. Eur J Med Chem. 2026;302 (Pt 2) :118321. doi:10.1016/j.ejmech.2025.118321